ASCO GU 2021: EV-301 Confirms Benefits of Enfortumab Vedotin for Previously-Treated Advanced Urothelial Carcinoma
This represents a novel option in a setting where effective therapies are limited
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.